The Dow's losing streak, fertilizer prices, Novo Nordisk's new Wegovy shot and more in Morning Squawk

Here are five key things investors need to know to start the trading day.

CNBC • 2 hours ago

China expresses hopes over Novo Nordisk's presence in market

China ​hopes Novo Nordisk ‌will "continue to cultivate ​the ​Chinese market and ⁠contribute ​to building ​a healthy China," said Ling ​Ji, ​China's vice commerce ‌minister, ⁠during a meeting with an ​executive ​VP ⁠from the ​Danish drugmaker ​on ⁠Friday, the ministry ⁠said.

Reuters • an hour ago

India's weight-loss drug boom: Novo Nordisk talks about GLP-1 generics after patent expiry

The patent on semaglutide, found in Novo Nordisk's Ozempic and Wegovy weight-loss drugs, expired in India on March 20. Vikrant Shrotriya, managing director at Novo Nordisk India, talks about how generics could reshape the market.

CNBC International TV • 7 hours ago

FDA Approves Novo Nordisk's Higher-Dose Wegovy for Obesity Patients

NVO wins FDA's accelerated nod for a higher 7.2 mg Wegovy dose, backed by strong phase III weight-loss data, with a U.S. launch planned for April 2026.

Zacks Investment Research • an hour ago

Lilly GLP-1 drug rivals Novo's pipeline treatment on gut side effects but throws up skin concern

New trial data complicates the competitive picture in the fast-growing obesity drug market Eli Lilly and Co's (NYSE:LLY) experimental weight-loss and diabetes drug retatrutide has shown a side-effect profile broadly comparable to leading treatments, but new data flagging an unusual skin reaction could give prescribers pause as the race to challenge Novo Nordisk's dominance intensifies. Lilly reported headline results from the first phase three trial of retatrutide in type 2 diabetes, showing patients achieved 16.8% weight loss and a 1.1 percentage point reduction in HbA1c, a standard measure of long-term blood sugar control, after 40 weeks at the 12mg dose.

Proactive Investors • 3 hours ago

US FDA approves higher dose of Wegovy

Novo Nordisk ​said ‌on Thursday the ​U.S. ​Food and ⁠Drug ​Administration has ​approved a high ​dose ​of Wegovy to ‌reduce ⁠excess body weight ​and ​maintain ⁠weight reduction ​long ​term.

Reuters • a day ago

FDA approves higher dose version of weight loss drug Wegovy as Novo Nordisk tries to win back market share

The Food and Drug Administration approved a higher dose version of Novo Nordisk's blockbuster weight loss injection Wegovy, as the company pushes to win back market share from Eli Lilly. The high-dose Wegovy helped patients with obesity lose an average 20.7% of their weight after 72 weeks in a phase three trial.

CNBC • a day ago

Novo Nordisk patent expiry opens door to cheaper weight-loss drugs in India

India's market for diabetes and weight-loss drugs is set for a shake-up as Danish drugmaker Novo Nordisk's patent on semaglutide expires this week, triggering a ​wave of cheaper generics from local drugmakers and worries about uneven oversight in an overcrowded market.

Reuters • Mar 19, 2026

1 Reason I'm Never Selling Novo Nordisk Stock

Novo Nordisk has been a leader in its core market for decades. This grants the pharmaceutical giant several advantages.

The Motley Fool • Mar 19, 2026

Novo Nordisk Secures FDA Approval For Higher-Dose Wegovy

• Novo Nordisk shares are experiencing downward pressure. What's pulling NVO shares down?

Benzinga • 21 hours ago